Everything on Pharma Strategy

Orion Pharma's heavy reliance on the Nubeka drug partnership with Bayer creates a high-growth but concentrated revenue stream, with over 50% of its revenue tied to this single asset.

Impact: While current growth is strong, the company faces significant risk from patent expiration in 2033, requiring successful pipeline diversification to sustain valuation.

— from Midterm Election Market Shifts and Pharma Winners · OHNE AKTIEN WIRD SCHWER - Tägliche Börsen-News· Nov 05, 2026

Eli Lilly’s valuation is supported by a diversified pipeline extending beyond weight-loss drugs into oncology and psychedelics. This reduces reliance on a single blockbuster product compared to competitors.

Impact: Companies with diversified therapeutic portfolios are better positioned to sustain long-term growth and command valuation premiums in the pharma sector.

— from Eli Lilly, DoorDash, and AI Infrastructure Trends · OHNE AKTIEN WIRD SCHWER - Tägliche Börsen-News· Oct 30, 2026